Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure
Clinical trial NCT02159872 · COMPLETED
Trial details
- NCT number
- NCT02159872
- Sponsor
- M.D. Anderson Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-18
- Primary completion
- 2020-04-14
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.